LEN vs VRCA · rev $34.19B vs rev $7.6M
LEN (LEN) versus Verrica Pharmaceuticals Inc (VRCA) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Verrica Pharmaceuticals Inc (VRCA) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported VRCA revenue for 2024-12-31 was $7.6M. Net income was -$76.6M. Revenue was up 47.7% from 2023-12-31 to 2024-12-31. VRCA currently screens at market cap $79.7M.
LEN currently screens at market cap $0. VRCA currently screens at market cap $79.7M.
Not investment advice. Open the LEN and VRCA stock pages for the full models.
Not investment advice.